SLC2A1 and Alzheimer disease: Indeed, in the Slc2a1 deficient APPSw/0 AD mouse model there is exacerbated AD pathology exemplified by accelerated microvascular degeneration, blood flow reductions, BBB breakdown, accelerated Aβ pathology and reduced clearance, attenuated neuronal activity, and more severe neurodegeneration [258].